News & Updates

The use of dexmedetomidine in the intensive care unit (ICU) appears to lower the risk of new-onset atrial fibrillation (AF) in patients, according to a study.

Treatment with dapagliflozin leads to lower incidence of total heart failure (HF) events and cardiovascular death, regardless of patient characteristics such as ejection fraction, according to a study.

Premedication with dextromethorphan 1 hour prior to flexible bronchoscopy appears to alleviate cough slightly in patients under conscious sedation and on topical lignocaine, reports a recent study.

Individuals with atrial high-rates episodes (AHREs) are at greater risk of progression to atrial fibrillation (AF). But the good news is that treatment with antiarrhythmic medication appears to have a protective effect both on AHRE burden and AF risk.

The oral, small molecule Wee1 kinase inhibitor adavosertib exerts antitumour effects in patients with advanced recurrent or persistent uterine serous carcinoma, but this benefit appears to be limited by the drug’s tolerability, as shown in the single-arm, phase IIb ADAGIO study.

In the EPI-VITRAKVI study, the TRK* inhibitor larotrectinib reduces morbidity and the need for aggressive local therapies in children with infantile fibrosarcoma (IFS) compared with the current standard of care (SoC).